Global Migraine Drugs Market research

Migraine Drugs Comprehensive Study by Type (Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids}, Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig}), Application (Hospitals, Clinics, Household Use, Others), Route of Administration (Oral, Injectables, Others), Distribution Chanel (Hospital-Based Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2026

Migraine Drugs Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Migraine Drugs Market?

According to the Migraine Research Foundation, migraine is affecting 39 million men, women and children in the United States and 1 billion worldwide. A migraine is a severe, recurring and painful headache. Typically, a headache affects one half of the head and lasts for 2 to 72 hours. The patient may have associated symptoms like nausea, vomiting, sensitivity to light, sound and smell. Migraine pain is more common in women as compared to men. There is currently no single cure for a migraine. Migraine treatment is aimed at preventing a full-blown attack and alleviating the symptoms that occur. Recently H. Lundbeck A/S and Alder BioPharmaceuticals (Alder) announced a definitive agreement for Lundbeck to acquire Alder. Alder is a clinical-stage biopharmaceutical company committed to transforming migraine treatment through the discovery, development and commercialization of novel therapeutic antibodies.

The market study is being classified by Type (Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids} and Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig}), by Application (Hospitals, Clinics, Household Use and Others) and major geographies with country level break-up.

Allergan (Ireland), Endo International (Ireland), GlaxoSmithKline (United States), Impax Laboratories, LLC (United States), Pfizer (United States), Abbott (United States), Johnson & Johnson (United States), Avanir Pharmaceuticals, Inc. (United States), Dr. Reddy’s Laboratories (India) and Merck & Co. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Zogenix (United States), Teva Pharmaceutical Industries (Israel), Novartis AG (Switzerland), Sanofi SA (France), H. Lundbeck A/S (Denmark) and Alder BioPharmaceuticals (United States).

Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Migraine Drugs market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Migraine Drugs market by Type, Application and Region.

On the basis of geography, the market of Migraine Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increase in Migraine Prevalence
  • Hectic Lifestyle of the People
  • Increase in Female Population Suffering from Migraine

Market Trend
  • High Demand for Anti-Migraine Devices and Headbands

Restraints
  • Side Effects of the Drugs Affecting the Growth of the Market

Opportunities
  • Demand for Total Cure Medications for Migraine in the Market
  • Increasing Awareness Regarding the Treatment
  • Growing Number of Online Pharmacies

Challenges
  • Lack of Proper Diagnosis
  • Less Awareness among the People in Developing Countries


On 17th May 2018, Novartis and Amgen announced that the United States Food and Drug Administration has approved Erenumab (Aimovig) to prevent migraine in adults.


Key Target Audience
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies and End-user

Report Objectives / Segmentation Covered

By Type
  • Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids}
  • Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig}
By Application
  • Hospitals
  • Clinics
  • Household Use
  • Others
By Route of Administration
  • Oral
  • Injectables
  • Others

By Distribution Chanel
  • Hospital-Based Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in Migraine Prevalence
      • 3.2.2. Hectic Lifestyle of the People
      • 3.2.3. Increase in Female Population Suffering from Migraine
    • 3.3. Market Challenges
      • 3.3.1. Lack of Proper Diagnosis
      • 3.3.2. Less Awareness among the People in Developing Countries
    • 3.4. Market Trends
      • 3.4.1. High Demand for Anti-Migraine Devices and Headbands
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Migraine Drugs, by Type, Application, Route of Administration, Distribution Chanel and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Migraine Drugs (Value)
      • 5.2.1. Global Migraine Drugs by: Type (Value)
        • 5.2.1.1. Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids}
        • 5.2.1.2. Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig}
      • 5.2.2. Global Migraine Drugs by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Household Use
        • 5.2.2.4. Others
      • 5.2.3. Global Migraine Drugs by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injectables
        • 5.2.3.3. Others
      • 5.2.4. Global Migraine Drugs by: Distribution Chanel (Value)
        • 5.2.4.1. Hospital-Based Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Migraine Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Migraine Drugs (Volume)
      • 5.3.1. Global Migraine Drugs by: Type (Volume)
        • 5.3.1.1. Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids}
        • 5.3.1.2. Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig}
      • 5.3.2. Global Migraine Drugs by: Application (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Clinics
        • 5.3.2.3. Household Use
        • 5.3.2.4. Others
      • 5.3.3. Global Migraine Drugs by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Injectables
        • 5.3.3.3. Others
      • 5.3.4. Global Migraine Drugs by: Distribution Chanel (Volume)
        • 5.3.4.1. Hospital-Based Pharmacies
        • 5.3.4.2. Retail Pharmacies
        • 5.3.4.3. Online Pharmacies
      • 5.3.5. Global Migraine Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Migraine Drugs (Price)
      • 5.4.1. Global Migraine Drugs by: Type (Price)
  • 6. Migraine Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Endo International (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Impax Laboratories, LLC (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Avanir Pharmaceuticals, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Dr. Reddy’s Laboratories (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck & Co. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Migraine Drugs Sale, by Type, Application, Route of Administration, Distribution Chanel and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Migraine Drugs (Value)
      • 7.2.1. Global Migraine Drugs by: Type (Value)
        • 7.2.1.1. Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids}
        • 7.2.1.2. Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig}
      • 7.2.2. Global Migraine Drugs by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Household Use
        • 7.2.2.4. Others
      • 7.2.3. Global Migraine Drugs by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injectables
        • 7.2.3.3. Others
      • 7.2.4. Global Migraine Drugs by: Distribution Chanel (Value)
        • 7.2.4.1. Hospital-Based Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Migraine Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Migraine Drugs (Volume)
      • 7.3.1. Global Migraine Drugs by: Type (Volume)
        • 7.3.1.1. Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids}
        • 7.3.1.2. Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig}
      • 7.3.2. Global Migraine Drugs by: Application (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Clinics
        • 7.3.2.3. Household Use
        • 7.3.2.4. Others
      • 7.3.3. Global Migraine Drugs by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Injectables
        • 7.3.3.3. Others
      • 7.3.4. Global Migraine Drugs by: Distribution Chanel (Volume)
        • 7.3.4.1. Hospital-Based Pharmacies
        • 7.3.4.2. Retail Pharmacies
        • 7.3.4.3. Online Pharmacies
      • 7.3.5. Global Migraine Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Migraine Drugs (Price)
      • 7.4.1. Global Migraine Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Migraine Drugs: by Type(USD Million)
  • Table 2. Migraine Drugs Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids} , by Region USD Million (2015-2020)
  • Table 3. Migraine Drugs Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig} , by Region USD Million (2015-2020)
  • Table 4. Migraine Drugs: by Application(USD Million)
  • Table 5. Migraine Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 6. Migraine Drugs Clinics , by Region USD Million (2015-2020)
  • Table 7. Migraine Drugs Household Use , by Region USD Million (2015-2020)
  • Table 8. Migraine Drugs Others , by Region USD Million (2015-2020)
  • Table 9. Migraine Drugs: by Route of Administration(USD Million)
  • Table 10. Migraine Drugs Oral , by Region USD Million (2015-2020)
  • Table 11. Migraine Drugs Injectables , by Region USD Million (2015-2020)
  • Table 12. Migraine Drugs Others , by Region USD Million (2015-2020)
  • Table 13. Migraine Drugs: by Distribution Chanel(USD Million)
  • Table 14. Migraine Drugs Hospital-Based Pharmacies , by Region USD Million (2015-2020)
  • Table 15. Migraine Drugs Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 16. Migraine Drugs Online Pharmacies , by Region USD Million (2015-2020)
  • Table 17. South America Migraine Drugs, by Country USD Million (2015-2020)
  • Table 18. South America Migraine Drugs, by Type USD Million (2015-2020)
  • Table 19. South America Migraine Drugs, by Application USD Million (2015-2020)
  • Table 20. South America Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 21. South America Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 22. Brazil Migraine Drugs, by Type USD Million (2015-2020)
  • Table 23. Brazil Migraine Drugs, by Application USD Million (2015-2020)
  • Table 24. Brazil Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 25. Brazil Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 26. Argentina Migraine Drugs, by Type USD Million (2015-2020)
  • Table 27. Argentina Migraine Drugs, by Application USD Million (2015-2020)
  • Table 28. Argentina Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 29. Argentina Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 30. Rest of South America Migraine Drugs, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Migraine Drugs, by Application USD Million (2015-2020)
  • Table 32. Rest of South America Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 33. Rest of South America Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 34. Asia Pacific Migraine Drugs, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Migraine Drugs, by Type USD Million (2015-2020)
  • Table 36. Asia Pacific Migraine Drugs, by Application USD Million (2015-2020)
  • Table 37. Asia Pacific Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 38. Asia Pacific Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 39. China Migraine Drugs, by Type USD Million (2015-2020)
  • Table 40. China Migraine Drugs, by Application USD Million (2015-2020)
  • Table 41. China Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 42. China Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 43. Japan Migraine Drugs, by Type USD Million (2015-2020)
  • Table 44. Japan Migraine Drugs, by Application USD Million (2015-2020)
  • Table 45. Japan Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 46. Japan Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 47. India Migraine Drugs, by Type USD Million (2015-2020)
  • Table 48. India Migraine Drugs, by Application USD Million (2015-2020)
  • Table 49. India Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 50. India Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 51. South Korea Migraine Drugs, by Type USD Million (2015-2020)
  • Table 52. South Korea Migraine Drugs, by Application USD Million (2015-2020)
  • Table 53. South Korea Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 54. South Korea Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 55. Taiwan Migraine Drugs, by Type USD Million (2015-2020)
  • Table 56. Taiwan Migraine Drugs, by Application USD Million (2015-2020)
  • Table 57. Taiwan Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 58. Taiwan Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 59. Australia Migraine Drugs, by Type USD Million (2015-2020)
  • Table 60. Australia Migraine Drugs, by Application USD Million (2015-2020)
  • Table 61. Australia Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 62. Australia Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Migraine Drugs, by Type USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Migraine Drugs, by Application USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 67. Europe Migraine Drugs, by Country USD Million (2015-2020)
  • Table 68. Europe Migraine Drugs, by Type USD Million (2015-2020)
  • Table 69. Europe Migraine Drugs, by Application USD Million (2015-2020)
  • Table 70. Europe Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 71. Europe Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 72. Germany Migraine Drugs, by Type USD Million (2015-2020)
  • Table 73. Germany Migraine Drugs, by Application USD Million (2015-2020)
  • Table 74. Germany Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 75. Germany Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 76. France Migraine Drugs, by Type USD Million (2015-2020)
  • Table 77. France Migraine Drugs, by Application USD Million (2015-2020)
  • Table 78. France Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 79. France Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 80. Italy Migraine Drugs, by Type USD Million (2015-2020)
  • Table 81. Italy Migraine Drugs, by Application USD Million (2015-2020)
  • Table 82. Italy Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 83. Italy Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 84. United Kingdom Migraine Drugs, by Type USD Million (2015-2020)
  • Table 85. United Kingdom Migraine Drugs, by Application USD Million (2015-2020)
  • Table 86. United Kingdom Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 87. United Kingdom Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 88. Netherlands Migraine Drugs, by Type USD Million (2015-2020)
  • Table 89. Netherlands Migraine Drugs, by Application USD Million (2015-2020)
  • Table 90. Netherlands Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 91. Netherlands Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 92. Rest of Europe Migraine Drugs, by Type USD Million (2015-2020)
  • Table 93. Rest of Europe Migraine Drugs, by Application USD Million (2015-2020)
  • Table 94. Rest of Europe Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 95. Rest of Europe Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 96. MEA Migraine Drugs, by Country USD Million (2015-2020)
  • Table 97. MEA Migraine Drugs, by Type USD Million (2015-2020)
  • Table 98. MEA Migraine Drugs, by Application USD Million (2015-2020)
  • Table 99. MEA Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 100. MEA Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 101. Middle East Migraine Drugs, by Type USD Million (2015-2020)
  • Table 102. Middle East Migraine Drugs, by Application USD Million (2015-2020)
  • Table 103. Middle East Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 104. Middle East Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 105. Africa Migraine Drugs, by Type USD Million (2015-2020)
  • Table 106. Africa Migraine Drugs, by Application USD Million (2015-2020)
  • Table 107. Africa Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 108. Africa Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 109. North America Migraine Drugs, by Country USD Million (2015-2020)
  • Table 110. North America Migraine Drugs, by Type USD Million (2015-2020)
  • Table 111. North America Migraine Drugs, by Application USD Million (2015-2020)
  • Table 112. North America Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 113. North America Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 114. United States Migraine Drugs, by Type USD Million (2015-2020)
  • Table 115. United States Migraine Drugs, by Application USD Million (2015-2020)
  • Table 116. United States Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 117. United States Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 118. Canada Migraine Drugs, by Type USD Million (2015-2020)
  • Table 119. Canada Migraine Drugs, by Application USD Million (2015-2020)
  • Table 120. Canada Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 121. Canada Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 122. Mexico Migraine Drugs, by Type USD Million (2015-2020)
  • Table 123. Mexico Migraine Drugs, by Application USD Million (2015-2020)
  • Table 124. Mexico Migraine Drugs, by Route of Administration USD Million (2015-2020)
  • Table 125. Mexico Migraine Drugs, by Distribution Chanel USD Million (2015-2020)
  • Table 126. Migraine Drugs Sales: by Type(K Units)
  • Table 127. Migraine Drugs Sales Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids} , by Region K Units (2015-2020)
  • Table 128. Migraine Drugs Sales Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig} , by Region K Units (2015-2020)
  • Table 129. Migraine Drugs Sales: by Application(K Units)
  • Table 130. Migraine Drugs Sales Hospitals , by Region K Units (2015-2020)
  • Table 131. Migraine Drugs Sales Clinics , by Region K Units (2015-2020)
  • Table 132. Migraine Drugs Sales Household Use , by Region K Units (2015-2020)
  • Table 133. Migraine Drugs Sales Others , by Region K Units (2015-2020)
  • Table 134. Migraine Drugs Sales: by Route of Administration(K Units)
  • Table 135. Migraine Drugs Sales Oral , by Region K Units (2015-2020)
  • Table 136. Migraine Drugs Sales Injectables , by Region K Units (2015-2020)
  • Table 137. Migraine Drugs Sales Others , by Region K Units (2015-2020)
  • Table 138. Migraine Drugs Sales: by Distribution Chanel(K Units)
  • Table 139. Migraine Drugs Sales Hospital-Based Pharmacies , by Region K Units (2015-2020)
  • Table 140. Migraine Drugs Sales Retail Pharmacies , by Region K Units (2015-2020)
  • Table 141. Migraine Drugs Sales Online Pharmacies , by Region K Units (2015-2020)
  • Table 142. South America Migraine Drugs Sales, by Country K Units (2015-2020)
  • Table 143. South America Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 144. South America Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 145. South America Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 146. South America Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 147. Brazil Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 148. Brazil Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 149. Brazil Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 150. Brazil Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 151. Argentina Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 152. Argentina Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 153. Argentina Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 154. Argentina Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 155. Rest of South America Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 156. Rest of South America Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 157. Rest of South America Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 158. Rest of South America Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 159. Asia Pacific Migraine Drugs Sales, by Country K Units (2015-2020)
  • Table 160. Asia Pacific Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 161. Asia Pacific Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 162. Asia Pacific Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 163. Asia Pacific Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 164. China Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 165. China Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 166. China Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 167. China Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 168. Japan Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 169. Japan Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 170. Japan Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 171. Japan Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 172. India Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 173. India Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 174. India Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 175. India Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 176. South Korea Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 177. South Korea Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 178. South Korea Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 179. South Korea Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 180. Taiwan Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 181. Taiwan Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 182. Taiwan Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 183. Taiwan Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 184. Australia Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 185. Australia Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 186. Australia Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 187. Australia Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 188. Rest of Asia-Pacific Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 189. Rest of Asia-Pacific Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 190. Rest of Asia-Pacific Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 191. Rest of Asia-Pacific Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 192. Europe Migraine Drugs Sales, by Country K Units (2015-2020)
  • Table 193. Europe Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 194. Europe Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 195. Europe Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 196. Europe Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 197. Germany Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 198. Germany Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 199. Germany Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 200. Germany Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 201. France Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 202. France Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 203. France Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 204. France Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 205. Italy Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 206. Italy Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 207. Italy Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 208. Italy Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 209. United Kingdom Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 210. United Kingdom Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 211. United Kingdom Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 212. United Kingdom Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 213. Netherlands Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 214. Netherlands Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 215. Netherlands Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 216. Netherlands Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 217. Rest of Europe Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 218. Rest of Europe Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 219. Rest of Europe Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 220. Rest of Europe Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 221. MEA Migraine Drugs Sales, by Country K Units (2015-2020)
  • Table 222. MEA Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 223. MEA Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 224. MEA Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 225. MEA Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 226. Middle East Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 227. Middle East Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 228. Middle East Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 229. Middle East Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 230. Africa Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 231. Africa Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 232. Africa Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 233. Africa Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 234. North America Migraine Drugs Sales, by Country K Units (2015-2020)
  • Table 235. North America Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 236. North America Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 237. North America Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 238. North America Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 239. United States Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 240. United States Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 241. United States Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 242. United States Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 243. Canada Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 244. Canada Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 245. Canada Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 246. Canada Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 247. Mexico Migraine Drugs Sales, by Type K Units (2015-2020)
  • Table 248. Mexico Migraine Drugs Sales, by Application K Units (2015-2020)
  • Table 249. Mexico Migraine Drugs Sales, by Route of Administration K Units (2015-2020)
  • Table 250. Mexico Migraine Drugs Sales, by Distribution Chanel K Units (2015-2020)
  • Table 251. Migraine Drugs: by Type(USD/Units)
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Migraine Drugs: by Type(USD Million)
  • Table 263. Migraine Drugs Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids} , by Region USD Million (2021-2026)
  • Table 264. Migraine Drugs Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig} , by Region USD Million (2021-2026)
  • Table 265. Migraine Drugs: by Application(USD Million)
  • Table 266. Migraine Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 267. Migraine Drugs Clinics , by Region USD Million (2021-2026)
  • Table 268. Migraine Drugs Household Use , by Region USD Million (2021-2026)
  • Table 269. Migraine Drugs Others , by Region USD Million (2021-2026)
  • Table 270. Migraine Drugs: by Route of Administration(USD Million)
  • Table 271. Migraine Drugs Oral , by Region USD Million (2021-2026)
  • Table 272. Migraine Drugs Injectables , by Region USD Million (2021-2026)
  • Table 273. Migraine Drugs Others , by Region USD Million (2021-2026)
  • Table 274. Migraine Drugs: by Distribution Chanel(USD Million)
  • Table 275. Migraine Drugs Hospital-Based Pharmacies , by Region USD Million (2021-2026)
  • Table 276. Migraine Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 277. Migraine Drugs Online Pharmacies , by Region USD Million (2021-2026)
  • Table 278. South America Migraine Drugs, by Country USD Million (2021-2026)
  • Table 279. South America Migraine Drugs, by Type USD Million (2021-2026)
  • Table 280. South America Migraine Drugs, by Application USD Million (2021-2026)
  • Table 281. South America Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 282. South America Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 283. Brazil Migraine Drugs, by Type USD Million (2021-2026)
  • Table 284. Brazil Migraine Drugs, by Application USD Million (2021-2026)
  • Table 285. Brazil Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 286. Brazil Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 287. Argentina Migraine Drugs, by Type USD Million (2021-2026)
  • Table 288. Argentina Migraine Drugs, by Application USD Million (2021-2026)
  • Table 289. Argentina Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 290. Argentina Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 291. Rest of South America Migraine Drugs, by Type USD Million (2021-2026)
  • Table 292. Rest of South America Migraine Drugs, by Application USD Million (2021-2026)
  • Table 293. Rest of South America Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 294. Rest of South America Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 295. Asia Pacific Migraine Drugs, by Country USD Million (2021-2026)
  • Table 296. Asia Pacific Migraine Drugs, by Type USD Million (2021-2026)
  • Table 297. Asia Pacific Migraine Drugs, by Application USD Million (2021-2026)
  • Table 298. Asia Pacific Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 299. Asia Pacific Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 300. China Migraine Drugs, by Type USD Million (2021-2026)
  • Table 301. China Migraine Drugs, by Application USD Million (2021-2026)
  • Table 302. China Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 303. China Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 304. Japan Migraine Drugs, by Type USD Million (2021-2026)
  • Table 305. Japan Migraine Drugs, by Application USD Million (2021-2026)
  • Table 306. Japan Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 307. Japan Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 308. India Migraine Drugs, by Type USD Million (2021-2026)
  • Table 309. India Migraine Drugs, by Application USD Million (2021-2026)
  • Table 310. India Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 311. India Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 312. South Korea Migraine Drugs, by Type USD Million (2021-2026)
  • Table 313. South Korea Migraine Drugs, by Application USD Million (2021-2026)
  • Table 314. South Korea Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 315. South Korea Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 316. Taiwan Migraine Drugs, by Type USD Million (2021-2026)
  • Table 317. Taiwan Migraine Drugs, by Application USD Million (2021-2026)
  • Table 318. Taiwan Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 319. Taiwan Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 320. Australia Migraine Drugs, by Type USD Million (2021-2026)
  • Table 321. Australia Migraine Drugs, by Application USD Million (2021-2026)
  • Table 322. Australia Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 323. Australia Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 324. Rest of Asia-Pacific Migraine Drugs, by Type USD Million (2021-2026)
  • Table 325. Rest of Asia-Pacific Migraine Drugs, by Application USD Million (2021-2026)
  • Table 326. Rest of Asia-Pacific Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 327. Rest of Asia-Pacific Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 328. Europe Migraine Drugs, by Country USD Million (2021-2026)
  • Table 329. Europe Migraine Drugs, by Type USD Million (2021-2026)
  • Table 330. Europe Migraine Drugs, by Application USD Million (2021-2026)
  • Table 331. Europe Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 332. Europe Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 333. Germany Migraine Drugs, by Type USD Million (2021-2026)
  • Table 334. Germany Migraine Drugs, by Application USD Million (2021-2026)
  • Table 335. Germany Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 336. Germany Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 337. France Migraine Drugs, by Type USD Million (2021-2026)
  • Table 338. France Migraine Drugs, by Application USD Million (2021-2026)
  • Table 339. France Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 340. France Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 341. Italy Migraine Drugs, by Type USD Million (2021-2026)
  • Table 342. Italy Migraine Drugs, by Application USD Million (2021-2026)
  • Table 343. Italy Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 344. Italy Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 345. United Kingdom Migraine Drugs, by Type USD Million (2021-2026)
  • Table 346. United Kingdom Migraine Drugs, by Application USD Million (2021-2026)
  • Table 347. United Kingdom Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 348. United Kingdom Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 349. Netherlands Migraine Drugs, by Type USD Million (2021-2026)
  • Table 350. Netherlands Migraine Drugs, by Application USD Million (2021-2026)
  • Table 351. Netherlands Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 352. Netherlands Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 353. Rest of Europe Migraine Drugs, by Type USD Million (2021-2026)
  • Table 354. Rest of Europe Migraine Drugs, by Application USD Million (2021-2026)
  • Table 355. Rest of Europe Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 356. Rest of Europe Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 357. MEA Migraine Drugs, by Country USD Million (2021-2026)
  • Table 358. MEA Migraine Drugs, by Type USD Million (2021-2026)
  • Table 359. MEA Migraine Drugs, by Application USD Million (2021-2026)
  • Table 360. MEA Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 361. MEA Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 362. Middle East Migraine Drugs, by Type USD Million (2021-2026)
  • Table 363. Middle East Migraine Drugs, by Application USD Million (2021-2026)
  • Table 364. Middle East Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 365. Middle East Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 366. Africa Migraine Drugs, by Type USD Million (2021-2026)
  • Table 367. Africa Migraine Drugs, by Application USD Million (2021-2026)
  • Table 368. Africa Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 369. Africa Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 370. North America Migraine Drugs, by Country USD Million (2021-2026)
  • Table 371. North America Migraine Drugs, by Type USD Million (2021-2026)
  • Table 372. North America Migraine Drugs, by Application USD Million (2021-2026)
  • Table 373. North America Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 374. North America Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 375. United States Migraine Drugs, by Type USD Million (2021-2026)
  • Table 376. United States Migraine Drugs, by Application USD Million (2021-2026)
  • Table 377. United States Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 378. United States Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 379. Canada Migraine Drugs, by Type USD Million (2021-2026)
  • Table 380. Canada Migraine Drugs, by Application USD Million (2021-2026)
  • Table 381. Canada Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 382. Canada Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 383. Mexico Migraine Drugs, by Type USD Million (2021-2026)
  • Table 384. Mexico Migraine Drugs, by Application USD Million (2021-2026)
  • Table 385. Mexico Migraine Drugs, by Route of Administration USD Million (2021-2026)
  • Table 386. Mexico Migraine Drugs, by Distribution Chanel USD Million (2021-2026)
  • Table 387. Migraine Drugs Sales: by Type(K Units)
  • Table 388. Migraine Drugs Sales Abortive Medications {Triptans, Ergots, Anti-nausea Medications, Opioid Medications and Glucocorticoids} , by Region K Units (2021-2026)
  • Table 389. Migraine Drugs Sales Preventive Medications {Cardiovascular Drugs, Antidepressants, Anti-Seizure Drugs, Pain Relievers, Botox and Aimovig} , by Region K Units (2021-2026)
  • Table 390. Migraine Drugs Sales: by Application(K Units)
  • Table 391. Migraine Drugs Sales Hospitals , by Region K Units (2021-2026)
  • Table 392. Migraine Drugs Sales Clinics , by Region K Units (2021-2026)
  • Table 393. Migraine Drugs Sales Household Use , by Region K Units (2021-2026)
  • Table 394. Migraine Drugs Sales Others , by Region K Units (2021-2026)
  • Table 395. Migraine Drugs Sales: by Route of Administration(K Units)
  • Table 396. Migraine Drugs Sales Oral , by Region K Units (2021-2026)
  • Table 397. Migraine Drugs Sales Injectables , by Region K Units (2021-2026)
  • Table 398. Migraine Drugs Sales Others , by Region K Units (2021-2026)
  • Table 399. Migraine Drugs Sales: by Distribution Chanel(K Units)
  • Table 400. Migraine Drugs Sales Hospital-Based Pharmacies , by Region K Units (2021-2026)
  • Table 401. Migraine Drugs Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 402. Migraine Drugs Sales Online Pharmacies , by Region K Units (2021-2026)
  • Table 403. South America Migraine Drugs Sales, by Country K Units (2021-2026)
  • Table 404. South America Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 405. South America Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 406. South America Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 407. South America Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 408. Brazil Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 409. Brazil Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 410. Brazil Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 411. Brazil Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 412. Argentina Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 413. Argentina Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 414. Argentina Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 415. Argentina Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 416. Rest of South America Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 417. Rest of South America Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 418. Rest of South America Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 419. Rest of South America Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 420. Asia Pacific Migraine Drugs Sales, by Country K Units (2021-2026)
  • Table 421. Asia Pacific Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 422. Asia Pacific Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 423. Asia Pacific Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 424. Asia Pacific Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 425. China Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 426. China Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 427. China Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 428. China Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 429. Japan Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 430. Japan Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 431. Japan Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 432. Japan Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 433. India Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 434. India Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 435. India Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 436. India Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 437. South Korea Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 438. South Korea Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 439. South Korea Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 440. South Korea Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 441. Taiwan Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 442. Taiwan Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 443. Taiwan Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 444. Taiwan Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 445. Australia Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 446. Australia Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 447. Australia Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 448. Australia Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 449. Rest of Asia-Pacific Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 450. Rest of Asia-Pacific Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 451. Rest of Asia-Pacific Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 452. Rest of Asia-Pacific Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 453. Europe Migraine Drugs Sales, by Country K Units (2021-2026)
  • Table 454. Europe Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 455. Europe Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 456. Europe Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 457. Europe Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 458. Germany Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 459. Germany Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 460. Germany Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 461. Germany Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 462. France Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 463. France Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 464. France Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 465. France Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 466. Italy Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 467. Italy Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 468. Italy Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 469. Italy Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 470. United Kingdom Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 471. United Kingdom Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 472. United Kingdom Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 473. United Kingdom Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 474. Netherlands Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 475. Netherlands Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 476. Netherlands Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 477. Netherlands Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 478. Rest of Europe Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 479. Rest of Europe Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 480. Rest of Europe Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 481. Rest of Europe Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 482. MEA Migraine Drugs Sales, by Country K Units (2021-2026)
  • Table 483. MEA Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 484. MEA Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 485. MEA Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 486. MEA Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 487. Middle East Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 488. Middle East Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 489. Middle East Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 490. Middle East Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 491. Africa Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 492. Africa Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 493. Africa Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 494. Africa Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 495. North America Migraine Drugs Sales, by Country K Units (2021-2026)
  • Table 496. North America Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 497. North America Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 498. North America Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 499. North America Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 500. United States Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 501. United States Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 502. United States Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 503. United States Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 504. Canada Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 505. Canada Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 506. Canada Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 507. Canada Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 508. Mexico Migraine Drugs Sales, by Type K Units (2021-2026)
  • Table 509. Mexico Migraine Drugs Sales, by Application K Units (2021-2026)
  • Table 510. Mexico Migraine Drugs Sales, by Route of Administration K Units (2021-2026)
  • Table 511. Mexico Migraine Drugs Sales, by Distribution Chanel K Units (2021-2026)
  • Table 512. Migraine Drugs: by Type(USD/Units)
  • Table 513. Research Programs/Design for This Report
  • Table 514. Key Data Information from Secondary Sources
  • Table 515. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Migraine Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global Migraine Drugs: by Application USD Million (2015-2020)
  • Figure 6. Global Migraine Drugs: by Route of Administration USD Million (2015-2020)
  • Figure 7. Global Migraine Drugs: by Distribution Chanel USD Million (2015-2020)
  • Figure 8. South America Migraine Drugs Share (%), by Country
  • Figure 9. Asia Pacific Migraine Drugs Share (%), by Country
  • Figure 10. Europe Migraine Drugs Share (%), by Country
  • Figure 11. MEA Migraine Drugs Share (%), by Country
  • Figure 12. North America Migraine Drugs Share (%), by Country
  • Figure 13. Global Migraine Drugs: by Type K Units (2015-2020)
  • Figure 14. Global Migraine Drugs: by Application K Units (2015-2020)
  • Figure 15. Global Migraine Drugs: by Route of Administration K Units (2015-2020)
  • Figure 16. Global Migraine Drugs: by Distribution Chanel K Units (2015-2020)
  • Figure 17. South America Migraine Drugs Share (%), by Country
  • Figure 18. Asia Pacific Migraine Drugs Share (%), by Country
  • Figure 19. Europe Migraine Drugs Share (%), by Country
  • Figure 20. MEA Migraine Drugs Share (%), by Country
  • Figure 21. North America Migraine Drugs Share (%), by Country
  • Figure 22. Global Migraine Drugs: by Type USD/Units (2015-2020)
  • Figure 23. Global Migraine Drugs share by Players 2020 (%)
  • Figure 24. Global Migraine Drugs share by Players (Top 3) 2020(%)
  • Figure 25. Global Migraine Drugs share by Players (Top 5) 2020(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Allergan (Ireland) Revenue, Net Income and Gross profit
  • Figure 28. Allergan (Ireland) Revenue: by Geography 2020
  • Figure 29. Endo International (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Endo International (Ireland) Revenue: by Geography 2020
  • Figure 31. GlaxoSmithKline (United States) Revenue, Net Income and Gross profit
  • Figure 32. GlaxoSmithKline (United States) Revenue: by Geography 2020
  • Figure 33. Impax Laboratories, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 34. Impax Laboratories, LLC (United States) Revenue: by Geography 2020
  • Figure 35. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 36. Pfizer (United States) Revenue: by Geography 2020
  • Figure 37. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 38. Abbott (United States) Revenue: by Geography 2020
  • Figure 39. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 40. Johnson & Johnson (United States) Revenue: by Geography 2020
  • Figure 41. Avanir Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Avanir Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 43. Dr. Reddy’s Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 44. Dr. Reddy’s Laboratories (India) Revenue: by Geography 2020
  • Figure 45. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 46. Merck & Co. (United States) Revenue: by Geography 2020
  • Figure 47. Global Migraine Drugs: by Type USD Million (2021-2026)
  • Figure 48. Global Migraine Drugs: by Application USD Million (2021-2026)
  • Figure 49. Global Migraine Drugs: by Route of Administration USD Million (2021-2026)
  • Figure 50. Global Migraine Drugs: by Distribution Chanel USD Million (2021-2026)
  • Figure 51. South America Migraine Drugs Share (%), by Country
  • Figure 52. Asia Pacific Migraine Drugs Share (%), by Country
  • Figure 53. Europe Migraine Drugs Share (%), by Country
  • Figure 54. MEA Migraine Drugs Share (%), by Country
  • Figure 55. North America Migraine Drugs Share (%), by Country
  • Figure 56. Global Migraine Drugs: by Type K Units (2021-2026)
  • Figure 57. Global Migraine Drugs: by Application K Units (2021-2026)
  • Figure 58. Global Migraine Drugs: by Route of Administration K Units (2021-2026)
  • Figure 59. Global Migraine Drugs: by Distribution Chanel K Units (2021-2026)
  • Figure 60. South America Migraine Drugs Share (%), by Country
  • Figure 61. Asia Pacific Migraine Drugs Share (%), by Country
  • Figure 62. Europe Migraine Drugs Share (%), by Country
  • Figure 63. MEA Migraine Drugs Share (%), by Country
  • Figure 64. North America Migraine Drugs Share (%), by Country
  • Figure 65. Global Migraine Drugs: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Allergan (Ireland)
  • Endo International (Ireland)
  • GlaxoSmithKline (United States)
  • Impax Laboratories, LLC (United States)
  • Pfizer (United States)
  • Abbott (United States)
  • Johnson & Johnson (United States)
  • Avanir Pharmaceuticals, Inc. (United States)
  • Dr. Reddy’s Laboratories (India)
  • Merck & Co. (United States)
Additional players considered in the study are as follows:
Zogenix (United States) , Teva Pharmaceutical Industries (Israel) , Novartis AG (Switzerland) , Sanofi SA (France) , H. Lundbeck A/S (Denmark) , Alder BioPharmaceuticals (United States)
Select User Access Type

Key Highlights of Report


Jan 2021 223 Pages 75 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Migraine Drugs Market research Quantitative research analysis
Global Migraine Drugs Market research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increase in Migraine Prevalence " is seen as one of major growth factors of Migraine Drugs Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Migraine Drugs Market research Report?

Have a Query? Click Here

Other Related Reports

Dental Bone Graft Substitutes Comprehensive Study by Type (Synthetic Bone Grafts, Alloplast, Allograft, Xenograft), Application (Sinus Lift, Ridge Augmentation, Socket Preservation), Distribution Cha...
$ 3450
DHA Powder Comprehensive Study by Type (Alage DHA Powder, Fish Oil DHA Powder, Others), Application (Infant Formula, Dietary Supplements, Food and Beverage, Others), Distribution Channel (Online, Off...
$ 3500
Podophyllin Comprehensive Study by Type (Less than 20 % Concentration of Podophyllin, 20%-50 % Concentration of Podophyllin, More than 50 % Concentration of Podophyllin), Application (Tincture, Crea...
$ 3450
Yeast Expression Vector Comprehensive Study by Type (K. Lactis Expression Vectors, Pichia Pastoris Expression Vectors, Saccharomyces Cerevisiae Expression Vectors, Others), Application (Therapeutic, ...
$ 3450
Caprylic Acid Comprehensive Study by Application (Epilepsy, Nerve Disorder, Kidney Failure, Digestive Disorders, Chylothorax, Other), Distribution Channel (Online, Offline), End User (Pharmaceuticals...
$ 3800
Antifungal Agents Comprehensive Study by Type (Echinocandins, Azoles, Ployenes, Allylamines, Others), Application (Powders, Ointments, Drugs, Pastes), Indications (Aspergillosis, Dermatophytosis, Can...
$ 3500